Evidence map›Paper›PMID 42012779›Full record

ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026

Interleukin-23 Inhibitors in Inflammatory Bowel Disease.

Pierluigi Puca, Simone Parello, Stefania Colantuono, Antonio Tursi, Gaetano Coppola, Loris Riccardo Lopetuso, Franco Scaldaferri, Antonio Gasbarrini, Alfredo Papa

Abstract readReview
In one paragraph

Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pierluigi PucaDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy. pierluigi.puca@unicatt.it.ORCID http://orcid.org/0000-0003-0935-8853
Simone ParelloDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Stefania ColantuonoIBD Unit, CEMAD-Centre for the cure of Digestive Diseases, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.
Antonio TursiTerritorial Gastroenterology Service, ASL Barletta-Andria-Trani (BT), Rome, Italy.
Gaetano CoppolaIBD Unit, CEMAD-Centre for the cure of Digestive Diseases, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.
Loris Riccardo LopetusoIBD Unit, CEMAD-Centre for the cure of Digestive Diseases, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.
Franco ScaldaferriDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Antonio GasbarriniDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Alfredo PapaDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selective inhibition of interleukin-23 (IL-23) has emerged as a highly effective therapeutic strategy in inflammatory bowel disease, targeting a central pathway of chronic intestinal inflammation while preserving host defense mechanisms. Across phase II and phase III randomized controlled trials, risankizumab, mirikizumab, and guselkumab consistently demonstrated robust efficacy in both ulcerative colitis and Crohn's disease, achieving clinical remission rates approaching 40-50% in ulcerative colitis and exceeding 50% in Crohn's disease during maintenance, with parallel improvements in endoscopic and histological outcomes. Notably, mirikizumab and guselkumab showed particularly high rates of endoscopic and histological remission in ulcerative colitis, whereas guselkumab achieved some of the highest induction remission rates in Crohn's disease. These benefits were durable over time, with long-term extension studies confirming sustained remission beyond two years in a substantial proportion of patients. Across trials, IL-23 inhibitors displayed a favorable safety profile, with low rates of serious adverse events, infections, and major cardiovascular events, supporting their use in long-term disease management. Real-world evidence further reinforces these findings, demonstrating consistent effectiveness in heavily pretreated and complex patient populations, including those with prior biologic failure, comorbidities, or difficult-to-treat disease phenotypes. In particular, risankizumab has shown strong performance in multi-refractory Crohn's disease cohorts, while emerging data for mirikizumab confirm its effectiveness in real-life ulcerative colitis settings. Beyond clinical outcomes, differences in molecular structure, pharmacokinetics, and Fc-mediated interactions may contribute to subtle distinctions among agents, potentially influencing therapeutic positioning. Ongoing development of oral compounds and combination strategies targeting complementary inflammatory pathways is expected to further expand the role of IL-23 inhibition. Overall, interleukin-23 inhibitors represent a cornerstone of modern inflammatory bowel disease therapy, combining high efficacy, durable responses, and an excellent safety profile, with growing evidence supporting their use across a broad spectrum of patients.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesInterleukin-23AnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHumansAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedguselkumabInterleukin-23risankizumab

Identifiers

PMID42012779
PMCPMC13212390

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.